NASDAQ (USD): RAPT Therapeutics, Inc. (RAPT)
Last Price
1.77
Today's Change
+0.03 (1.72%)
Day's Change
1.55 - 1.79
Trading Volume
3,526,841
You are setting up a price and signal alert with 15 minutes delay. Click here to enjoy real-time price and signal alerts.
T4Q
31-Mar-2021
2020
2019
2018
2017
Cash from operating activities
238
-1.64%
1000
+11.55%
110
+81.66%
900
-13.16%
600
+235.36%
MQ Chat
Send individual or group chats with anyone on i3investor
MQ Trader
Earn MQ Points while trading with MQ Trader
MQ Affiliate
Earn side income from Affiliate Program
MQdemy
Online learning and teaching marketplace
1
CEO Morning Brief
Losses From Crypto Hacks Jump to US$2.2b in 2024 — Report
2
Bitcoin Tests US$100,000 After Fed Spurs Worst Drop Since September
3
Google to Fight Japan’s Claims That It Hobbles Rivals in Search
4
US New-home Sales Rebound in November After Storm-stricken Month
5
Orders for US Business Equipment Rise by Most in Over a Year
#
Stock
Score
RAPT
RAPT Therapeutics, Inc.
AGN
833
RELI
Reliance Global Group, Inc.
666
CYN
Cyngn Inc.
PLTR
Palantir Technologies Inc.
500
6
TSLA
Tesla, Inc.
7
GOOGL
Alphabet Inc.
8
NVDA
NVIDIA Corporation
9
AAPL
Apple Inc.
10
BABA
Alibaba Group Holding Limited
366
Last
Change
Volume
SVMH
0.032
+0.004
255,957,908
LICN
0.489
-1.631
183,350,854
LITM
0.585
+0.202
132,990,791
QUBT
15.14
-10.54
120,604,778
LMDX
0.016
-0.018
120,553,903
LILM
0.209
-0.334
112,784,715
MU
87.09
-16.81
87,924,604
762.00
-84.71
85,558,284
AVGR
1.75
+1.10
85,348,947
RGTI
12.22
+1.26
76,078,059
BRK-A
684,468.64
+2,469.62
489
AZO
3,279.57
+37.34
15,201
BKNG
5,096.22
+33.10
21,579
FCNCA
2,157.26
+29.30
8,919
MSTR
354.77
+22.54
7,134,470
TPL
1,161.50
+22.05
22,718
451.65
+21.05
32,665,166
BH-A
1,296.00
+19.85
172
FNGU
662.05
+19.73
192,499
MKL
1,755.06
+18.14
8,220
MELI
1,774.05
-343.25
2,940,447
1,309.00
-138.99
2,237,917
1,395.13
-102.30
318,280
NOW
643.29
-87.83
5,025,012
MEDP
357.30
-79.88
1,004,401
MDB
236.06
-73.94
10,812,930
MCK
547.51
-70.00
4,067,959
RYVLX
562.73
-43.79
0
RYVYX
562.54
-43.78
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....